Advice

in the absence of a submission from the holder of the marketing authorisation:

bosutinib (Bosulif®) is not recommended for use within NHSScotland.

Indication under review: Treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice88KB (PDF)

Download

Medicine details

Medicine name:
bosutinib (Bosulif)
SMC ID:
SMC2109
Indication:
For treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia.
Pharmaceutical company
Pfizer Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
13 August 2018